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AbstrAct
Patients with cancer are subjected to several imaging 
examinations which frequently require the administration 
of contrast medium (CM). However, it has been estimated 
that acute kidney injury (AKI) due to the injection of 
iodinated CM accounts for 11% of all cases of AKI, and 
it is reported in up to 2% of all computed tomography 
(CT) examinations. Remarkably, the risks of developing 
AKI are increased in the elderly, in patients with chronic 
kidney disease or diabetes, and with dehydration or 
administration of nephrotoxic chemotherapeutics. Given 
the common occurrence of post- contrast acute kidney 
injury (PC- AKI) in clinical practice, primary care physicians 
and all specialists involved in managing patients with 
cancer should be aware of the strategies to reduce the 
risk of this event. In 2018, a panel of five experts from the 
specialties of radiology, oncology and nephrology were 
speakers at the annual meeting of the Italian Society of 
Medical Radiology (Società Italiana di Radiologia Medica 
e Interventistica), with the aim of commenting on existing 
evidence and providing their experience on the incidence 
and management of PC- AKI in patients with cancer. The 
discussion represented the basis for this white paper, 
which is intended to be a practical guide organised by 
statements describing methods to reduce renal injury risks 
related to CM- enhanced CT examinations in patients with 
cancer.
IntroduCtIon
The role of contrast medium- enhanced 
computed tomography (CECT) is extremely 
important throughout the whole natural 
history of patients with cancer, being key to 
correctly characterise and stage the disease, 
to monitor response to anticancer treatments 
and to monitor the risk of progression or 
relapse during follow- up.
Furthermore, the increased survival 
achieved in the past decades, due to improve-
ments in the treatment of a number of malig-
nancies, is associated with a growing number 
of patients with cancer with an active disease, 
or in follow- up after treatment, or aged 70 
years or more1; these patients are therefore 
expected to present a number of comorbid-
ities,2 including acute and chronic kidney 
disease (CKD).
Thus, contrast medium (CM)- related renal 
damage is worthy of attention, representing 
one of the key topics covered by the recently 
born subspecialty of onconephrology.3
A consensus- based paper, established on 
a modified Delphi approach, on methods 
to reduce risks related to computed tomog-
raphy (CT) examinations in patients with 
cancer has already been recently published.2 
In order to better focus on CM- induced renal 
damage, a multidisciplinary panel of experts 
from the specialties of radiology, oncology 
and nephrology assembled in 2018. Their 
specific aim was to comment on existing 
evidence and to provide their experience 
on the incidence and management of acute 
kidney injury (AKI) in patients with cancer 
who receive iodinated CM. The discussion 
represented the basis for this white paper, 
which is intended to be a practical guide 
organised by statements (some of which were 
already provided in the article by Del Mastro 
et al2). In particular, clinical questions, which 
were derived from clinical needs, and an inte-
gration of all the expert’s suggestions, are 
stated further. The statements and the recom-
mendations appear in italics in the boxes.
Patients with cancer are subjected to several 
imaging examinations, which frequently 
require the administration of iodinated CM.4 5 
However, it has been estimated that AKI due 
to injection of iodinated CM accounts for 
11% of all cases of AKI, and it is reported in 
up to 2% of all CT examinations.5
There are many causes of AKI following 
iodinated CM administration, not directly 
caused by CM, so that AKI is often mistakenly 
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should an iodinated cM injection be considered a 
relevant risk factor for AKI?
 ► The administration of iodinated CM is a well- known risk factor for 
AKI.
 ► AKI in patients undergoing iodinated CM injections may be due to 
the CM itself or to other concomitant risk factors, leading to different 
definitions of AKI in this setting: contrast- induced AKI (CI- AKI) versus 
post- contrast AKI (PC- AKI).
 ► Whenever it is impossible to clearly differentiate between these two 
definitions, the term PC- AKI should be used.
Is AKI a clinical issue in patients with cancer?
 ► AKI should be defined as SCr levels of ≥0.3 mg/dL or ≥25% within 
48–72 hours.
 ► The incidence of AKI in patients with cancer ranges from 12% to 
17%, and it is higher than the incidence observed in patients with-
out cancer (5–8%).
 ► Risk factors include the type of cancer, comorbidities, cotreatment 
with other drugs (eg, furosemide, antibiotics, chemotherapy and io-
dinated CM administration).
 ► Specific cancer locations (eg, kidney, liver, oesophagus, pancre-
as and uterus) and cancer types (lymphomas, leukaemias, mixed 
lymphosarcoma and multiple myeloma) have been linked with an 
increased risk of AKI.
 ► Among commonly used anticancer agents (either cytotoxic chemo-
therapeutics, targeted agents or immune checkpoint inhibitors), an 
increased risk of AKI has been documented particularly in patients 
treated with pemetrexed, ifosfamide, cisplatin, bevacizumab and 
cetuximab.
 ► A short time span between chemotherapy administration and CM 
injection is associated with an increased risk of AKI. Closely repeat-
ed administrations of iodinated CM are associated with a higher risk 
of PC- AKI.
attributed to CM; this led to the development of the 
European Society of Uroradiology (ESUR) definition of 
‘PC- AKI’, which is used to describe a decrease in renal 
function that follows intravascular administration of CM, 
but it is not strictly caused by CM; PC- AKI is thus defined 
as an increase in serum creatinine (SCr) of >0.3 mg/dL 
(or >26.5 µmol/L), or >1.5 times the baseline, within 
48–72 hours of intravascular administration of a contrast 
agent.6
Instead, the term CI- AKI should only be used when the 
causative relationship between AKI and CM administra-
tion is proven, a relationship which is often difficult to 
establish. Thus, throughout the whole manuscript, we did 
use the term PC- AKI.
In oncological patients, PC- AKI is often multifactorial, 
highlighting the need to consider and weight each of the 
possible causes involved (age, oncological treatments, use 
of other nephrotoxic agents and dehydration).7
As far as PC- AKI in clinical practice is concerned, 
primary care physicians and all specialists involved in 
managing patients with cancer should be aware of the 
strategies to reduce the risk of this event.
AKI is highly prevalent in patients with cancer, particu-
larly in the case of renal cell cancer, liver cancer, multiple 
myeloma, leukaemias and lymphomas.8 9 In a Danish 
population study, including 37 267 patients with cancer, 
the risk of AKI (defined as >50% increase in SCr levels) 
was approximately 17.5% within 1 year of a cancer diag-
nosis and 27% after 5 years.8 The rate of AKI in hospital-
ised patients with cancer seems to be higher than the rate 
reported for hospitalised patients without cancer (12 vs 
5–8%, respectively).9–11
Therefore, patients with cancer should be considered a 
population at high risk of developing AKI, and this condi-
tion is associated with major consequences on patients’ 
status and a great impact on the healthcare system.9 Sala-
hudeen et al9 evaluated the effects of AKI on the clinical 
outcomes and costs related to hospital stays for patients 
with cancer. They reported a 4.7- fold increase in death, 
a 3- day increase in the length of hospital stay and a 
US$42 671 increase in costs for hospitalised patients with 
cancer, in comparison with those without. Moreover, the 
mortality rate in patients with AKI is higher in patients 
with cancer (42.8%) than in patients without cancer 
(22.5%) (p=0.014).12
A number of factors and patient characteristics 
contribute to the increased risk of developing AKI in 
patients with cancer.13 Furthermore, the odd ratio (OR) 
for developing AKI is significantly higher for cancer 
patients with diabetes (OR 1.89, 95% CI 1.51 to 2.36), 
those undergoing chemotherapy (OR 1.61, 95% CI 1.26 
to 2.05), patients with hyponatraemia (OR 1.97, 95% CI 
1.57 to 2.47), patients who use antibiotics (OR 1.52, 
95% CI 1.15 to 2.02) and those undergoing an intrave-
nous injection of iodinated CM (OR 4.55, 95% CI 3.51 to 
5.89) compared with those without the aforementioned 
characteristics.9 Other risk factors are heart failure, a 
recent myocardial infarction (<1 month), hypertension, 
pre- existing CKD and age over 70 years.14 Moreover, some 
types of cancer are associated with higher risk of devel-
oping AKI; namely, patients with cancer originating in the 
oesophagus, kidney, liver, pancreas or uterus and patients 
affected by lymphomas, leukaemia, mixed lymphosar-
coma or multiple myeloma are considered to be at a very 
high risk, with a ≥15% probability of developing AKI 
compared with those with other types of cancer.9
According to all the aforementioned data, it is possible 
to identify some characteristics that make a patient 
with cancer particularly prone to develop AKI. Table 1 
summarises characteristics of patients which, according 
to existing evidence and the clinical experience of the 
authors, can be associated with a high risk of developing 
AKI. In addition, current ESUR guidelines extensively 
discuss the different risks of developing PC- AKI.6
Medications play a critical role in inducing AKI; indeed, 
according to the Renal Insufficiency and Anticancer 
Medications study,15 50–60% of patients with cancer who 
are undergoing antineoplastic treatment develop a renal 
impairment, a figure higher than the incidence of PC- AKI 
itself. Beyond anticancer agents, oncological patients 
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Table 1 Identification of patients at risk of developing PC- AKI, who should undergo prevention strategies
Factor High- risk features Medium- risk features Low- risk features
Renal function Established CKD or
GFR <30 mL/min/1.73m2 or 
<45mL/min/1.73 m2
GFR 30-45 mL/min/1.73 m2 GFR 45-60 mL/min/1.73 m2
Age (years) ≥70 ≥60 <60
Heart failure NYHA class >III or EF <30% NYHA class <III or EF <35% NYHA class I or EF <45%
Volume of CM (mL) ≥250 140–250 <140 
Diabetes Uncontrolled Controlled with concomitant 
systemic diseases
Controlled without concomitant 
systemic diseases
Hb (g/L) <95 <110 <145
Nephrotoxic drugs Three concomitant Two concomitant One
Time of administration of 
oncological therapy and 
iodinated CM (days)
<8 <45 <45
Patients at high risk are those with at least one high- risk feature+one medium- risk feature, those with at least three medium- risk features 
or those carrying at least five low- risk features.
CKD, chronic kidney disease; CM, contrast medium; EF, ejection fraction; GFR, glomerular filtration rate; Hb, haemoglobin; NYHA, New 
York Heart Association; PC- AKI, post- contrast acute kidney injury.
are indeed exposed to multiple nephrotoxic insults, 
including antibiotics, analgesics and drugs for supportive 
therapy (eg, bisphosphonates).
Cisplatin is by far the most common cause of acute 
nephrotoxicity from anticancer agents; it typically causes 
glomerular impairment and tubulopathy, which ulti-
mately leads to magnesuria and hypomagnesaemia.16 The 
incidence and severity of renal toxicity increases with the 
repeated use of cycles of cisplatin- based chemotherapy, 
ultimately leading to an irreversible damage.
Cisplatin- treated patients with cancer receiving iodin-
ated CM during radiological procedures are at a higher 
risk of PC- AKI. Indeed, exposure to iodinated CM within 
1 week before cisplatin administration increased the risk 
of AKI by 2.56- fold.17 Furthermore, the risk of PC- AKI was 
2.56- fold higher (95% CI 1.28 to 5.11) in patients exposed 
to CM within 1 week before cisplatin administration than 
in patients without such exposure (p=0.009).18
Cicin et al reported an incidence of PC- AKI after chemo-
therapy in hospitalised patients with cancer of 20%.13 
Moreover, AKI developed 4.5 times more frequently in 
patients with cancer who had undergone injection of 
iodinated CM and underwent a CT scan within 45 days 
after their last chemotherapy treatment (p=0.005), thus 
proving iodinated CM injection to be an independent 
risk factor (p=0.017). In patients with cancer who require 
CECT in an emergency setting, the OR of developing 
PC- AKI (in this case defined as an increase in SCr levels 
of ≥0.5 mg/dL or ≥25% within 48–72 hours) was 4.09 
(95% CI 1.34 to 12.56) in patients requiring serial exam-
inations on consecutive days, compared with patients who 
only underwent scans on 1 day.19 However, the presence 
of a confounding factor must be acknowledged; that is, 
patients requiring serial examination are often under-
going multiple treatments and are in a poorer health 
status and hence are at an inherently higher risk of AKI.
Despite this, the aforementioned evidence highlights 
the need to prevent the risk of PC- AKI in patients with 
cancer, especially in at- risk patients, such as those treated 
with cisplatin or other potentially nephrotoxic agents, or 
in those with pre- existing CKD and diabetes, or in elderly 
subjects.20–22
We should highlight that, in the real world, we simply 
cannot wait 45 days between chemotherapy and iodin-
ated CM administration, especially considering that many 
cytotoxic agents are administered at intervals of 2, 3 or 
4 weeks.
Another key point to keep in mind is that, beyond 
cisplatin, a number of other anticancer agents (eg, 
targeted agents and immune checkpoint inhibitors) may 
induce glomerular injury, tubulopathies as well as inter-
stitial nephritis.23–25 Thus, since almost all patients with 
cancer on active treatment undergo a number of CECT 
scans, the risk of an increased nephrotoxicity is particu-
larly high, not to take into account the fact that patients 
on clinical trials usually undergo very closely repeated 
iodinated CM administration in order to monitor the 
activity of experimental treatments.
role of hydration and n-acetylcisteine
Prehydration with saline infusion is the only recom-
mended measure to prevent AKI in the setting of CM 
infusion, as demonstrated by the results of the PRESERVE 
(Prevention of Serious Adverse Events Following Angiog-
raphy) study, which enrolled patients scheduled for angi-
ography.26 The proposed dose regimen for pre- CM admin-
istration was 1–3 mL/kg/hour, to be started between 2 
and 12 hours before the radiological procedure.
A systematic review and meta- analysis showed that, in 
patients undergoing any contrast- enhanced procedure, 
sodium bicarbonate significantly decreased the risk of 
PC- AKI, without a significant difference in need for renal 
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Table 2 Formulas for lean body mass calculation
Formula Males Females
James39 45 eLBM=1.1 W–128(W/H)2 eLBM=1.07W–148(W/H)2
Boer36 42 eLBM=0.407W+0.267 hour - 19.2 eLBM=0.252W+0.473 hour - 48.3
eLBM, estimated lean body mass; H, body height (cm); W, body weight (kg).
Pc- AKI prevention strategy: which kind of prophylaxis and 
on which patients?
 ► PC- AKI should be prevented, whenever possible, in cancer patients 
at risk of AKI.
 ► Overall, prehydration and the use of tailored dose of iodinated CM in 
patients at high risk are recommended.
 ► A preventive strategy using saline prehydration, as well as the use 
of the CM with the lowest osmolarity, is highly advisable, particularly 
in high- risk patients.
 ► Iso- osmolar contrast medium (IOCM) should thus be considered 
the first choice in this setting, particularly if patients with cancer 
present a high risk of developing AKI (eg, they present diabetes, 
liver diseases, hypertension, pre- existing CKD, low hematocrit, age 
over 70 years, cardiac diseases and recent myocardial infarction 
(<1 month)).
replacement therapy, in- hospital mortality or congestive 
heart failure compared with controls. Similar results were 
seen for the risk of PC- AKI when sodium bicarbonate was 
compared with normal saline alone, but not when sodium 
bicarbonate/N- acetylcysteine combination was compared 
with N- acetylcysteine/normal saline combination.27
However, these results have been challenged by another 
meta- analysis,28 as well as by the already mentioned 
PRESERVE study26 and by the AMACING randomised 
trial,29 and thus cannot be considered as definitive. In 
particular, in the AMACING trial, no prophylaxis was 
found to be non- inferior and cost- saving in preventing 
PC- AKI when compared with intravenous hydration.29
Although studies on oral hydration are limited, prelimi-
nary evidence on this strategy suggests that it is as safe and 
effective as intravenous prophylaxis.30 For this reason, 
when it is not possible to hydrate the patient by the intra-
venous route, at least oral hydration is recommended.
As far as N- acetylcysteine is concerned, its role to reduce 
the incidence of PC- AKI is controversial.31 At the current 
time, there is insufficient evidence of its efficacy to recom-
mend its use.32 33
Finally, renal replacement therapy has not been shown 
conclusively to reduce the risk of PC- AKI in patients 
receiving intravenous or intra- arterial CM, and its use is 
not recommended.32
Selection of iodinated CM according to different guidelines
Current guidelines (eg, ESUR, The American College 
of Cardiology Foundation (ACCF), the American Heart 
Association (AHA), Kidney Disease: Improving Global 
Outcome (KDIGO), American Society of Nephrology 
(ASN) and American College of Radiology (ACR)) do 
not provide consistent recommendations for the selec-
tion of iodinated CM in patients with cancer in order to 
limit the risk of developing AKI. Furthermore, the ESUR 
guidelines consider low the risk of PC- AKI in the general 
population, and for this reason, they suggest prevention 
only in patients with a glomerular filtration rate (GFR) 
of <30 mL/min.32 Several other guidelines recommend 
that iodinated CM with the lowest osmolarity and the 
lowest toxicity should be used, and that Iso- osmolar 
contrast medium (IOCM) should be administered in 
high- risk patients. The guidelines of ACCF and AHA 
recommend the use of IOCM as a strategy to prevent 
AKI in patients with stable ischaemic heart disease,34 and 
KDIGO confirms a preference towards the use of IOCM 
in patients with CKD.22 Based on the Onconephrology 
Curriculum of the ASN, high- osmolar (>1400 mOsm/kg) 
and low- osmolar (600–800 mOsm/kg) CM are associated 
with a higher incidence of AKI compared with IOCM 
(300 mOsm/kg).20 In addition, the Geriatric Nephrology 
Curriculum of the ASN suggests the preference of iodix-
anol when iodinated CM is used in elderly patients.21
The 2018 ACR Manual on Contrast Media highlights 
the fact that a number of studies have failed to establish 
a clear advantage of intravenous IOCM over intravenous 
low- osmolarity contrast medium (LOCM) with regard 
to PC- AKI or CIN.33 Indeed, a 2009 meta- analysis using 
data pooled from 25 trials found no difference in the rate 
of PC- AKI between iodixanol and low- osmolarity agents 
after intravenous administration.35
As a whole, radiologists’ guidelines have a more gener-
alist approach in comparison with cardiological and 
nephrological guidelines; the latter defines the risk 
in specific settings of patients and suggests preventive 
measures, such as hydration and IOCM use in at- risk 
patients.
Given the lack of consistent indications, we review here 
current evidence on the selection and optimisation of 
iodinated CM in patients with cancer.
Dose
It has been demonstrated that the enhancement of liver 
parenchyma, during portal phase, should increase by at 
least 50–60 Hounsfield units to allow an accurate identi-
fication of focal lesions.36 37 The parenchymal enhance-
ment is determined by the concentration of iodine in the 
extracellular and vascular volumes; thus, it is also influ-
enced by the patient’s weight. Therefore, the amount of 
iodinated CM should be tailored for each patient. The 
CM dose should be calculated according to milligrams 
of iodine (mgI) rather than volume in millilitres. Studies 
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suggested tailoring the amount of CM based on patients’ 
lean body weight (LBW) rather than on total body weight 
(TBW).38 39 Indeed, injecting 750 mgI/kg of patient LBW 
to maximise lesion detection rate was suggested.40 This 
approach seems to overcome the limit of the previous 
strategy whereby the CM amount required was estimated 
based on TBW. In fact, the estimation of CM dose at CT 
based on LBW reduces the contribution of highly variable 
but poorly perfused adipose tissue, especially in obese 
patients. Different methods are available to calculate 
LBW, and the James formula is one the most commonly 
used (table 2).38 41 However, this formula seems to have 
shortcomings in obese patients (body mass index of 
>30 kg/m2), underestimating patients’ LBW and conse-
quently the amount of CM to be injected. Thus, other 
formulas, like the Boer formula,42 may be more appro-
priate.42–45 Finally, a recent study demonstrated that the 
adoption of a bioimpedance device to tailor CM dose 
based on LBW in obese patients can result in an optimal 
liver enhancement in the portal phase during MDCT 
(multidetector computed tomography) of the liver and it 
should be preferred to the approach of calculating LBW 
with formulas.15
Another parameter influencing hypervascular liver 
lesion enhancement and thus their detectability is the 
iodine delivery rate (IDR). A minimum IDR of 1.2 gram 
of iodine (gI) per second has been suggested using a stan-
dard acquisition protocol at 120 kV.17 46
Recent technological developments (ie, availability of 
new image reconstruction algorithms, such as iterative 
reconstructions of second and third generations, and 
more powerful tube generators), allow lowering of the 
tube voltage (ie, kV) during the CT acquisition protocol. 
A low kV scanning protocol (ie, 80 kV) increases tissue 
contrast enhancement, since iodine better absorbs X- ray 
photons at low energy because X- rays are closer to the 
iodine k- edge, and, at the same time, low kV means lower 
radiation exposure compared with conventional 120 kV 
acquisition protocols. In two recent papers, the authors 
delivered between 330 and 360 mgI/kg, achieving the 
same image quality of traditional protocols, but being 
also able to reduce radiation exposure by 50%.47 48
Further developments can be expected by the use of 
dual- energy scanners with optimisation of low kilovoltage 
peak virtual monochromatic images.49
Osmolarity of iodinated CM
Though the nephrotoxicity of first- generation iodinated 
CM, which were characterised by high osmolarity, has 
been clearly demonstrated, several recent propensity 
score- matched controlled observational studies have 
failed to show any association between AKI and modern 
iodinated CM.50 The lack of association between AKI and 
modern CM administered intravenously before CT exam-
ination may be the result of a better adherence to existing 
guidelines, with proper patient selection and preventive 
measures.50
A bulk of evidence suggests that the osmolarity of 
iodinated CM does play a major role in the risk of devel-
oping AKI.50–52 From a mechanistic viewpoint, consistent 
evidence from cultured tubular cells suggests that LOCM 
has more severe cytotoxic effects than IOCM.50 In addi-
tion, in animal models, IOCM is associated with a lower 
induction of Nox4- dependent reactive oxygen species 
generation. Furthermore, IOCM also exerts fewer vaso-
constriction effects than LOCM.53
Indeed, evidence suggests that AKI is more frequent 
when using LOCM, but may not occur when using IOCM 
together with an adequate prophylaxis. In a large meta- 
analysis of 25 studies, the relative risk of developing 
CI- AKI (defined by the authors as an increase in SCr of 
either ≥0.5 mg/dL or ≥25% from baseline) with intra- 
arterial iodixanol—an IOCM—compared with LOCM was 
0.462 (95% CI 0.272 to 0.786, p=0.004).52 Similar findings 
were reported in another meta- analysis,51 although this 
superiority may lose significance according to the type of 
analysis. Concerning intravenous administration, a study 
conducted by Nguyen et al, which enrolled patients with 
decreased renal function, showed an inferior incidence 
of PC- AKI in patients treated with iodixanol (8.5%) 
compared with the iopromide group (27.8%, p=0.012).54 
To date, a single randomised, prospective, comparative 
study has been conducted in relatively young (<60 years 
old) patients with cancer at a very low risk of PC- AKI, 
defined here as a GFR of >60 mL/min. The mean GFR 
was 98.8 mL/min in the iopromide group and 96.5 mL/
min in the iodixanol group. These results suggested a 
lower incidence of AKI in patients who have undergone 
an intravenous injection of IOCM (4/247; ie, 1.6%), 
compared with iopromide (p=0.045), suggesting a more 
favourable safety profile of iodixanol versus iopromide.55 
IOCM proved also to be safe for kidney function in two 
studies involving chronic dialysis patients, independently 
of the route of administration (intravenous vs intra- 
arterial); indeed, the use of iodixanol did not result in 
further increase of SCr.56 57 The CONNECT(Clinical Eval-
uation Of Remote NotificatioN to rEduCe Time to Clinical 
Decision) Italian observational study showed that in the 
setting of hospital CT radiology units, where guideline- 
recommended strategies for PC- AKI prevention may not 
be consistently followed, the use of the IOCM iodixanol 
appears to be associated with a lower incidence of PC- AKI 
in at- risk patients. The majority (76.4%) of patients refer-
ring to CT radiology units had one risk factor and 19.8% 
had two risk factors; while relatively few patients had three 
risk factors (3.4%) or four risk factors (0.4%). Notably, 
the concomitance of two risk factors has an additive effect 
on PC- AKI risk.58
CONCLuSIONS
AKI is a serious and frequent concern in patients with 
cancer who often present comorbidities or receive 
drugs that may increase the risk of developing this 
event. Therefore, it should be mandatory to try to 
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prevent PC- AKI (as recently defined by Lencioni et al58) 
in patients with cancer at risk, with the implementa-
tion of dedicated protocols (an example, based on the 
experience of the authors, is presented in figure 1). 
In particular, prehydration and the choice of specific 
CM doses and classes (IOCM vs LOCM) in patients at 
high risk are recommended: a preventive strategy using 
saline prehydration, as well as the use of the CM with 
the lowest osmolarity, is highly advisable, particularly in 
high- risk patients. IOCM should thus be considered the 
first choice in this setting.
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